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New selective thiolate gold(I) complexes inhibit proliferation of different 
human cancer cells and induce apoptosis in primary cultures of mouse 
colon tumors
Elisa Abas,a Raquel Pena-Martinez,a Diego Aguirre-Ramírez,b Antonio Rodriguez-Dieguez,e Mariano Laguna,*, 
a and Laura Grasa*,b,c,d
New thiolate gold(I) complexes with P(NMe2)3 (HMPT) as a phosphane group have been synthesized [Au(SR)(HMPT)] (R= Spy, Spyrim, 
SMe2pyrim, Sbenzothiazole, Sthiazoline, Sbenzimidazole and 2-thiouracil). All of them have been characterized, including X-Ray studies 
of complexes with SMe2pyrim, Sbenzothiazole and 2-thiouracil moieties. In addition, their potential application as anticancer drugs has 
been analyzed by determining their pharmacokinetic activity (water solubility, cell permeability and BSA transport protein affinity). Based 
on the good results of these experiments, we carried out studies of cell viability with our compounds on different cell lines (A2780, 
A2780R and Caco-2/TC7 cells), showing more cytotoxic activity than cisplatin in all cases. Besides, two of the synthesized complexes 
exhibited specific selectivity for cancerous Caco-2 cells, arising complexes with Sbenzimidazole and 2-thiouracil groups, as potential 
candidates for anticancer drugs. These complexes were able to induce a strong inhibition of the thioredoxin reductase (TrxR) protein 
and oxidative damage in membrane lipids. Additional studies in primary cultures from mouse colon tumors showed that these two 
complexes are proapoptotic by the exposure of phosphatidylserine. Based on our results, we conclude that two of our thiolate gold(I) 
complexes are good and effective candidates to be used in chemotherapy.
Introduction
The human body, as every living organism, is composed of 
millions of cells in a continuous process of growing, dividing 
and dying. This process, known as cell cycle, is tightly 
controlled by several check points which ensure the correct 
DNA replication, but sometimes a mutation can be omitted 
and corrupted DNA proliferates. Mutations can be inherited, 
which suppose only the 10% of mutations, or be a result of 
DNA damage by environmental factors, such as the harmful 
substances in tobacco smoke (chemical carcinogens), UV 
radiation from sunlight (physical carcinogens) or the human 
papillomavirus (biological carcinogens).1 These mutations 
usually imply tumorgenesis.2, 3 Thus, as it can be inhered the 
more cell proliferation processes the more sensitive the 
tissue is. This is why colorectal cancer (CRC) is the third most 
commonly diagnosed cancer and the second highest cause of 
cancer death in 2018,4, 5 because up to 1010 cells are daily 
replaced in a human colon.6 Nowadays, there is still not a drug 
capable to fight against cancer by itself and two or more drugs 
are required to struggle the uncontrolled proliferation of 
cancer cells. Based on this fact, one of the most urgent 
objectives of medicinal chemistry is the discovery of novel 
and more effective and selective drugs against cancer. 
Bioinorganic chemistry already provides different examples 
of metal complex-based drugs whose antitumor activity is 
well known: among them, cisplatin is one of the most 
frequently used clinical anticancer drugs. Much has been 
researched since the discovery of cisplatin, and as a result 
new generations of platinum based drugs have been 
developed. One of them, oxaliplatin is still used in the 
treatment of CRC, in combination with 5-fluoracil and 
leucovin (FOLFOX).7 Nevertheless, platinum drugs are well 
known due to their lack of selectivity and their severe side 
effects. It is believed that both facts are closely related and 
based on the mechanism of action. DNA is the main target for 
platinum drugs, but these compounds not only damage the 
DNA present in cancer but also in normal cells. Therefore, 
scientists are focused on the development of new 
organometallic complexes as effective as platinum but more 
selective, what means complexes mechanistically different. 
Although different metals would be able to be good 
candidates, the therapeutic use of gold and its complexes 
dates back to medieval ages and the Renaissance.8 Despite 
this, the synthesis of new derivates based on gold for 
chemotherapy is still a developing area of medicinal and 
pharmaceutical chemistry.9-12 Application of gold complexes 
is expanded from their use in rheumatoid arthritis treatment 
until their employ as antimalarial agents and now in 
chemotherapy.13 The most widely known gold complex with 
pharmacological properties is auranofin, which represents an 
important milestone in the development of anticancer drugs 
based on Au(I)–phosphane complexes.14-20 Auranofin’s 
structure has served as a model to new gold drugs, where 
gold(I) center presents two different bonds, one to the S-
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atom of the thioglucose, and another one to the P-atom of 
the phosphane moiety (Figure 1). Owing to the soft acidic 
nature of gold(I), it is understandable that the gold(I) center 










Figure 1. Structure of auranofin.
Phosphorus- and Sulphur-containing nucleophiles are widely used 
as ligands to enhance the stability of the resulting gold(I) 
complexes under physiological conditions, that is why the 
phosphanegold(I) thiolate derivatives constitute a family of very 
promising experimental agents for cancer treatment.11, 19, 21, 22 In 
addition to the chemical issue, the coordination sphere of the 
metallic center has to be carefully selected in order to give good 
physicochemical properties to the final complex, like water 
solubility and lipophilicity among others. In fact, a good balance 
between these two properties is critical for a good distribution in 
the organism by the bloodstream. The lipophilicity is directly 
related to the diffusion and permeation into the cellular lipid layer 
membrane, thus affecting not only to the activity of the drug, but 
also to its toxicity to healthy tissues. Moreover, lipophilicity is also 
related to plasma protein binding and metabolism of the drug.23 
Water solubility is also an important property, since it can 
influence on the absorption and distribution of the molecule. 
Mechanistically, although the precise target of gold species is still 
under debate, most of the investigations have unveiled that their 
cytotoxicity is due to their ability to alter mitochondrial functions 
through their binding to Se-containing enzymes like thioredoxin 
reductase (TrxR)11, 24 and thioredoxin glutathione reductase; 
however, only a modest inhibitory effect is found on glutathione 
reductase.25, 26 Thioredoxin reductase (TrxR) is an important and 
ubiquitous enzyme critically involved in the regulation of 
intracellular metabolism. Besides, the thioredoxin/thioredoxin 
reductase system plays a crucial role in the defense against 
oxidative damage and thus, in redox signaling. The interaction 
between gold-based organometallic drug and TrxR seems to lead 
to inhibition of the enzyme. As a result, there is an increase of the 
reactive oxygen species (ROS) and consequently, cell death via 
apoptosis.25, 27 TrxR system is an excellent target because it is 
overexpressed in tumor cells,28, 29 which implies more tendency of 
the gold drugs to these kind of cells and therefore, more selectivity 
than other organometallic complexes. In previous works, we have 
reported that the use of water soluble phosphanes of the type 
1,3,5-triaza-7-phosphaadamantane (PTA), has led to water soluble 
gold(I) derivatives with antitumor properties against ovarian 
and/or colon cancer cells.15, 16, 18, 19, 30 In this study, we report the 
tailored design of a new family of phosphanegold(I) thiolate with 
another even more water soluble phosphane, hexamethyl 
phosphorous triamide (HMPT). In addition, the gold(I) center is 
coordinated to different aromatic thiolate ligands, which have 
been selected due to their solubility and their demonstrated 
antiproliferative activity in other gold derivatives.
Results and discussion 
Synthesis and characterization
The conventional route for the synthesis of thiolate 
gold(I)derivatives consists of the addition of [AuCl(HMPT)] (1) to a 
solution of the thiol in the presence of a base. All the obtained 
complexes are air stable solids with the formula [Au(SR)(HMPT)] 
(SR: Spy 2, Spyrim 3, SMe2pyrim 4, Sbenzothiazole 5, Sthiazoline 6, 










































Scheme 1. Preparation of gold(I) derivatives with HMPT.
The coordination of the SR ligand can be confirmed by IR 
spectroscopy, thanks to the Au−Cl stretching vibration. This band 
is clearly visible in the complex 1 spectrum at 320 cm-1, but it 
disappears after the reaction with the thiolate in all cases. Besides, 
aromatic bands are also appreciable, although the different rings 
of the thiol group are better characterized by 1H NMR. In addition 
of the ring signals, all of them show the characteristic signal of the 
HMPT phosphane, a doublet signal of the 18 protons in their 1H 
NMR spectra. The 31P{1H} NMR displays a low-field displaced 
singlet compared to those in the free phosphane, but at higher 
field respect to the starting material [AuCl(HMPT)] (1) as a 
consequence of the coordination to the SR ligand (Table 1).
Table 1. 31P {1H} NMR shifts for [Au(SR)HMPT] complexes.
31P{H}NMR 1 2 3 4 5 6 7 8
δ(ppm) 110.87 124.05 124.05 124.43 121.06 122.8 120.78 120.88
Crystallographic Studies
Suitable crystals for X-ray structure determination were grown 
from complexes 4, 5 and 8. The structures reveal the typical linear 
two-coordinated geometry of the Au(I) cation with the angles S-
Au-P being 173.35(5)° and 178.03(4)° respectively. The crystal 
group and system are different for each complex, whereas 
complex 4 crystallizes in P-1 triclinic group, complex 5 does in 
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P21/c monoclinic group. The length of Au-P distances in complex 1 
is 2.222(3) Å,31 the same bond Au-P in complexes 4 and 5 shows 
very similar lengths, 2.2623(13) and 2.2643(11) Å,  as there is no 
additional steric effects or repulsion to take into account. Besides, 
although the AuAu distance for complex 5 is longer than for 
complex 4, 6.635 (for 4) and 9.397 (for 5) Å, in both cases these 
distances are larger than the sum of vdW radii, so there is no 
aurophilic interaction between metal centers (Figure 2). 
Figure 2. X-Ray structures for complexes 4 and 5. AuAu distances 
are represented in green.
Crystal of complex 8 was grown and measured by X-Ray diffraction. 
Although the data of this crystal structure high quality, they are 
good enough to allow a preliminary study of the complex. This 
study permits to observe intermolecular H-bonds between a NH 
unit from one 2-thiouracile molecule and the oxygen of the 
carbonyl group from other neighbor ligand. AuAu distance is 
5.375 Å so, and no metal interaction is observed (Figure 3). 
Figure 3. A. H bonds observed for complex 8. B. Au-Au distances 
are represented in green.
The intermolecular interactions of these three complexes are very 
different. Complex 4 presents a strong stacking interaction 
between the aromatic rings (3.357 Å), which generates a 
bimolecular entity (Figure S2). Nevertheless, complex 5 does not 
establish this kind of interactions, so no different molecules are 
stacked in bigger units. It is worth to be mentioned the case of 
complex 8 where a double and stronger interaction can be 
observed. This interaction is provoked by the hydrogen bond 
between N6 and O3 atoms, and on the other hand N11 and O2 
atoms (Figure S3), with distances of 2.839 and 2.754 respectively. 
These double interactions contribute to the stabilization of 
bimolecular entities in the crystalline structure.
Lipophilicity
It is necessary for a drug to have certain ADMET-tox properties, 
being some of them water solubility, lipophilicity, permeability or 
stability. The first two are very important but what is more crucial 
is the balance between them. It is known that membrane cell is 
composed of lipids, in contrast to the intracellular medium which 
is aqueous, so to get a good biodistribution, a drug has to possess 
both properties balanced (lipophilicity and hydrophilicity). To 
study these two properties, firstly water solubility measures were 
performed (Table 2). Despite the carefully structural design of our 
complexes with the presence of a water soluble phosphane and a 
lipophilic thiol, they seem not be so water soluble as we expected. 
In fact, they are less soluble than complex 1, which is coherent with 
the larger size of the thiol group compare to the chlorine atom. 
Nevertheless, as it was mentioned before, water solubility is not 
determinant, but it is the balance of hydro- and lipophilicity. This 
characteristic can be measured by partition coefficient 
water/octanol, log P (for neutral complexes). In this work, we used 
the shake-flask method 32 to study the distribution of our 
complexes in aqueous and n-octanol media. The physicochemical 
similarity of 1-octanol to lipids makes it the most appropriate 
hydrophobic solvent. High values of lipophilicity of gold(I) 
complexes usually implies high toxicity because the drug is 
accumulated in the mitochondria 33, 34. This is why a correct design 
of the drug is needed and the incorporation of hydrophilic moieties 
in the complexes is more and more common. The ideal ranges of 
lipophilicity for orally administrated drugs have been indicated to 
be 0 ≤ log P ≤ 3, so according to the experimental data obtained 
(Table 2), all gold(I) complexes show good values of LogP7.4, and 
could be considered potentially oral drugs. 
Table 2. Distribution coefficients of complexes 1-8.35
Cis-Pt Auranofin 1 2 3 4 5 6 7 8
Water Solubility (mg/L) 1.235 460 103 180 220 140 300 189 330
Log P7.4 -0.5320 2.5335 0.76 0.93 1.02 1.10 0.98 0.74 0.89 0.66
As it can be observed, the more H-bond donor atoms are in the 
molecule, the closer to zero are the LogP7.4 values, which is normal 
because these atoms increase the probability of water solubility. 
Besides, the size of the thiol residue is something to take into 
account, because water solubility is easier for small molecules. 
These factors are consequent with the fact that complex 8 
presents the least value for this property. On the other hand, we 
studied the impact of the both units of the complex, phosphane 
and thiol group, in order to establish the better phosphane moiety 
or thiol ligand to use, being this fact a crucial step in the correct 
design of a drug. Based on the Table 3 it may be inferred that the 
use of HMPT is positive to achieve a balanced Log P7.4. In contrast, 
the ionic character of the [PTA-R]+ derivatives makes the gold(I) 
complexes too water soluble, with the exception of the PTA-CH2-
p-(NO2-Ph) phosphane.
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Table 3. Evaluation of the impact of phosphane (HMPT, this work 
and [PTA-R]+ Ref. 14, 15) and thiol unit on the Log P7.4 values of 










HMPT 0.93 1.02 1.10
PTA-CH2Ph 0.15 0.18 -0.48
PTA-CH2COOMe -0.30 -0.26 -0.46
PTA-CH2-p-(COOH-Ph) -0.44 -0.83 -0.81
PTA-CH2-p-(CH2COOH-Ph) -0.35 -0.88 -0.79
PTA-CH2-p-(NO2-Ph) 1.03 1.24 1.20
Solution Stability Studies.
Based on the distribution coefficient values of our complexes, a 
proper uptake can be assumed, but once the complex reaches the 
intracellular medium, several processes may be held. The 
intracellular medium is plenty of biomolecules which gold(I) center 
may interact with and thus, the complex may change its structure 
due to hydrolysis or redox reactions. Therefore, stability of the 
complexes has to be evaluated as another important 
pharmacokinetic property. Firstly, due to the poor water solubility 
observed, a previous solution in DMSO was required to perform 
the stability test. Each gold complex was dissolved in DMSO (6·10-
3 M) and then diluted in the corresponding working solvent at pH 
7.4, to a final concentration of 5·10-5 M. The solution stability of 
the complexes was analyzed by absorption UV−vis 
spectrophotometry over 24 h at 37 °C, in order to simulate 
physiological conditions. The first test was carried out in PBS buffer 
solution and no reduction processes were observed, whereas no 
new bands over 580 nm appear. These results are hopeful because 
the gold toxicity is usually due to the accumulation of gold(0). In 
several complexes, a slightly decrease of the intensity can be 
appreciated especially at 24 hours, which may point hydrolysis 
processes. Moving to a more complex environment, we worked in 
a solution of PBS with 20% (v/v) complete medium (Supplemented 
Dulbecco’s Modified Eagles medium (DMEM) see Experimental 
Section). This medium was selected because it is the cell culture 
medium, and it is important to test the stability in this medium in 
order to determine possible prodrug behavior. In the UV-vis 
spectra, a hyperchromic effect was observed in the 300 nm band 
(Figure 4), which is usually associated with the formation of Au-O 
bonds, something that could point hydrolysis processes.36 In 
contrast to the results in PBS buffer, in the presence of DMEM, 
reactions of reduction were observed for complex 7.













































Figure 4. UV-vis spectra of complex 7 (up) and 8 (down) in PBS 
with 20% (v/v) complete medium. 
Bovine Serum Albumin Interaction.
Most chemotherapeutic complexes benefit proteins present in 
bloodstream to achieve its target. Several are the proteins in 
plasma, but there is one more significant than the others, the 
human serum albumin (HSA); not only because of its major 
concentration (500-750 µM), but also because of its role in drug 
delivery.37 Thus, the interaction between albumin and the drug 
may determine the drug’s uptake and distribution. For this reason, 
the study of albumin binding is an important part to evaluate 
included in the mentioned ADME-tox properties. Its structure has 
been determined by X-ray diffraction and has been fully 
characterized. However, it is more frequent the use of the bovine 
serum albumin (BSA), as it is similar to HSA, with a homology of ca. 
76%, and commercially available. The structure of BSA has also 
been determined by X-ray diffraction and it is fully characterized. 
It contains 585 amino acids and two main binding sites I and II,38 
where substances can be bound. The strength of this interaction 
should be studied in order to evaluate if it is strong enough for 
transport but also weak to deliver the drug once the target is 
reached. In addition, BSA presents an intrinsic fluorescence, 
mainly due to two tryptophan residues: Trp134, found on the 
surface of the protein, and Trp212, located in a hydrophobic 
binding pocket.39  Most of the drugs are well biodistributed and 
delivered thanks to its binding to plasmatic proteins. This bond 
usually implies changes in many properties of the drug. To study 
the binding between the albumin and the compounds several 
techniques could be used, but in order to study albumin binding of 
gold complexes, fluorescence and UV-Vis spectroscopy are the 
most commonly used. A low protein binding seems to be 
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advantageous, since some authors have indicated a high affinity 
for protein thiols restricts the in vivo anticancer activity of  gold(I) 
complexes compared to its in vitro activity.40 In other words, a 
strong binding to albumin can limit the distribution of the drug 
thus limiting its effectiveness. In order to study the affinity of some 
of the new complexes synthesized for albumin, we have carried 
out some spectroscopic experiments of fluorescence. The intrinsic 
fluorescence of BSA is very sensitive to the environment, so a weak 
interaction with some molecules can produce changes in their 
emission spectrum. In this study we observed that the addition of 
increasing amounts of thiolate derivatives to a solution of BSA 
resulted in a quenching of its fluorescence emission upon 
excitation at 295 nm. The fluorescence data have been analyzed 
using the Stern-Volmer equation to quantify the strength of the 
binding between gold complex and BSA. To do this, it is necessary 
to plot F0/F versus [complex] (F0 = intensity in the absence of the 
quencher; F = intensity in the presence of the quencher), as it can 
























Figure 5. Stern−Volmer (A) and Modified Stern-Volmer (B) plots for 
the quenching of BSA with increasing amounts of gold(I) 
complexes (complex concentration from 0 to 170 (1), 43.8 (2 and 
7) 58.3 (2 and 8), 29.6 (4 and 5) and 72.6 (6) μM) at 298 K (λexc = 
295 nm, [BSA] = 50 μM).
The determination of the operated quenching of fluorescence 
gives useful information because while static quenching implies 
the formation of ground-state complex, in dynamic quenching only 
are diffusion processes.41 kq parameter is especially important in 
this study, the value of this constant indicates which type of 
quenching operates. Due to dynamic quenching depends on 
diffusion, a kq value higher than the diffusion controlled rate 
constant of the biomolecule in water, 1010 M−1 s−1, could indicate 
some type of binding interaction, implying a possible contribution 
of static quenching. In our case, the values of kq are in the order 
of 1011-13 M−1 s −1, so binding of the complexes and BSA could be 
considered (Table 3). Previously, it was mentioned that BSA 
contains different domains where drugs can bind, and thus more 
than one drug can be linked to the BSA. Stern-Volmer modified 
equation permits calculate the values of the binding constant (Kb) 
for each experiment and the number of binding sites (n) (Table 4). 
According with the results, there is only one gold molecule 
coordinated to BSA, and this bond is in agreement with those 
observed for other gold(I) derivatives,14, 17 but slightly larger than 
the binding constant of cisplatin.42 As it can be seen in Table 4, 
complex 1 presents a lower n value than the rest of the derivatives, 
so the substitution of the chloride atom for the thiol group is 
positive in order to achieve a better interaction between our 
complexes and BSA. Complex 1 seems to interact only with the half 
of the BSA molecules. 
Table 4. Values of the Stern−Volmer quenching constant (KSV), 
bimolecular quenching constant (Kq), number of binding sites (n) 
and binding constant (Kb) for the interaction of gold(I) complexes 
with BSA.
Complex Ksv (M-1) Kq (M-1 s-1) Kb (M-1) n
1 1.12·103 1.12·1011 0.59·102 0.58 (1)
2 4.95·102 4.95·1012 1.51·106 1.33 (1)
3 4.66·102 4.66·1012 2.83·106 1.43 (1)
4 1.25·105 1.25·1013 9.43·105 1.19 (1)
5 6.25·105 6.25·1013 2.57·108 1.57 (2)
6 8.24·103 8.24·1011 4.57·103 0.93 (1)
7 8.78·102 8.78·1012 5.35·105 1.18 (1)
8 2.83·103 2.83·1012 4.65·105 1.28 (1)
Cytotoxicity assays
All complexes synthesized were tested against different tumor cell 
lines: A2780, A2780R (ovarian cancer) and Caco2/TC7 (human 
colon adenocarcinoma). The IC50 values (Table 5) were calculated 
by using the MTT viability assay.43 
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Table 5.  IC50 values (µM) of gold(I) complexes in A2780 and 
A2780R cells (HMPT, this work and PTA Ref. 18, 19 ).
1 2 3 4 5 6 7 8
A2780
HMPT 0.86±0.01 0.76±0.01 0.70±0.01 0.26±0.01 0.7 ±0.01 0.47±0.02 0.99±0.02 0.41±0.03
PTA 9.6 ±2.3 5.7±1.9 0.7±0.1 0.8±0.2 0.7±0.3 8.0±0.6
A2780R
HMPT 2.70±0.01 1.27±0.02 1.44±0.02 0.64±0.01 2.12±0.02 0.94±0.01 2.34±0.02 0.93±0.01
PTA 8.2 ±2.8 4.1±2.5 0.8±0.5 0.9±0.1 1.1±0.1 23.9±2.51
The results are expressed as mean values ± log SEM (n ≥ 12 
experiments). 
Previous studies with different phosphane groups were done in 
our research group and allowed us to compare the cytotoxic 
influence of the phosphane. In this case, we can deduce that in 
A2780 and A2780R cell lines, the use of the phosphane HMPT 
enhances the antiproliferative activity compared to the observed 
with PTA. Besides, all of our complexes are strongly better than cis-
platin in both cell lines (4.30±0.5 for A2780 and 18.2±0.5 for 
A2780R).18 
In addition to this study, gold(I) derivatives were also tested on 
colon cancer Caco-2/TC7 cell line.44, 45 This cell line implies an extra 
advantage for our antitumor research, because once cells reach 
the state of differentiation, they acquire morphological properties 
of normal epithelial cells which allow us to evaluate the selectivity 
of all gold(I) complexes.44, 46 For this purpose, cytotoxicity 
experiments were carried out in cancer cells (5 days after seeding) 
and in normal cells (5 days after seeding).  Remarkably, as it can be 
seen in Table 6, complexes 7 and 8 do not show any effect on 
normal cells even at concentrations 5 fold higher than the IC50 
values obtained in cancer cells. For this reason, these two 
compounds are excellent candidates to perform additional studies 
about its action mechanisms. However, complexes 2-6 were no 
longer considered as candidates for antitumour application, as 
they reduced the viability of normal cells.
Our studies carried out in the Caco-2 cell line also show the great 
cytotoxic effect of all our complexes based on IC50 values in cancer 
cells. Although our complexes are not so active as auranofin 
(2.1±0.40 μM), they are better than cis-platin (45.6±8.08),47 not 
only due to their antiproliferative activity but also their selectivity.
Table 6.  IC50 values (µM) of gold(I) complexes in Caco2/TC7 cells.
IC50 2 3 4 5 6 7 8
Cancer cells 3.87±0.15 3.08±0.14 3.17±0.10 3.16±0.20 7.40±0.10 4.50±0.10 4.55±0.11
Normal cells 10.5±0.07 5.14±0.08 8.81±0.09 11.3±0.08 10.1±0.14 >>20 >>20
The results are expressed as mean values ± log SEM (n ≥ 12 
experiments). 
Based on the different activity observed for the phosphane in 
coordination to gold center in the ovarian cell line A2780, a similar 
study was performed with the Caco-2/TC7 cell line (Table 7). These 
results point to the high impact of the phosphane group in 
antiproliferative activity. In fact, IC50 values can vary from 
2.68±0.30 with the PTA-CH2-p-(COOH-Ph) to 7.67±1.50 with the 
unit PTA-CH2COOMe. 
Table 7. Evaluation of the impact of phosphane and thiol unit on 
the IC50 values (µM) of gold(I) complexes in Caco-2/TC7 cell line 










HMPT 3.87±0.15 3.08±0.14 3.17±0.10
PTA-CH2Ph 5.05±0.05 3.95±0.04 7.50±1.5
PTA-CH2COOMe 7.67±1.50 2.80±1.0 6.37±1.3
PTA-CH2-p-(COOH-Ph) 2.68±0.30 6.47±2.15 7.66±0.09
PTA-CH2-p-(CH2COOH-Ph) 4.61±0.14 10.66±2.56 6.29±1.07
PTA-CH2-p-(NO2-Ph) 3.08±0.79 2.98±1.28 3.96±1.33
The results are expressed as mean values ± log SEM (n ≥ 12 
experiments). 
Effects on Reactive Oxygen Species (ROS) generation. 
Interaction with TrxR Systems. Thioredoxin system has been 
generally considered one of the main targets of gold compounds. 
This system participates in the control of redox equilibrium of the 
cell by removing the excess of oxidant species. One of the reasons 
why Trx system is an appropriated target relies in its 
overexpression in some cancer cells in tumours, related to 
aggressive tumour growth and inhibition of apoptosis.29 Besides, 
the presence of cysteine and selenocysteine residues in the 
enzyme makes possible the binding with soft metals as gold(I). It is 
believed that the coordination of gold(I) and other metals to the 
TrxR results in its inhibition. The breaking of the equilibrium 
between oxidant and antioxidant species promotes the oxidative 
stress in the cell, leading to apoptosis processes.48, 49 We studied 
the inhibition of the thioredoxin reductase in Caco-2/TC7 cell 
lysates, in contrast with other investigations, in which isolated 
TrxR protein from rat liver is used.50, 51  A strong decrease of the 
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TrxR activity was observed for complexes 7 and 8 compared with 
the basal activity registered for the control lysate (Figure 6). The 
coordination of the gold(I) phosphane complexes seems to be 
selective to TrxR system comparing to the observed affinity  to 



































Figure 6.  Specific TrxR activity (units/ mg protein) in Caco-2/TC7 
cells with complexes 7 and 8 (20 µM, 24 h). *P<0.05; **P<0.01 vs. 
control (n ≥ 4 experiments). 
Stress Oxidative Damage. Based on the above results, we 
hypothesized that stress oxidative might be enhanced and 
consequently, damage on different biomolecules such as proteins 
and lipids might be present. So in the next step of the current 
investigation, we measure the products of proteins and lipids 
oxidation. Protein oxidation evaluation. Oxidation processes in 
proteins can give different products and thus, there are diverse 
methods to evaluate the damage on proteins, but the most 
established one is the quantification of carbonyl species.53 . 
Although proteins are very sensitive biomolecules, no evidence of 
oxidative damage was observed with the two gold(I) complexes 
used (Figure 7A). Lipid peroxidation evaluation. Lipids present in 
the membrane layer can also be easily oxidized to form 
peroxidised species such as malondialdehyde (MDA) or 
hydroxyalkenals (4-HDA), which are important biomarkers to 
evaluate lipid oxidative damage. In order to measure both 
biomarkers at the same time, we use Gerard-Monier method.54 In 
contrast with the observed in protein oxidation assay, now we 
found a significant increase in the MDA + 4-HDA levels after the 
treatment with complexes 7 and 8 respect to the DMSO-control 
(Figure 7B). These differences permit conclude that our complexes 
promote an oxidative damage in lipids of the cell membrane. Other 
studies point that the inhibition of the TrxR systems usually 
provokes the formation of hydrogen peroxide.24 This increase of 
hydrogen peroxide may trigger a signalling event of controlled cell 
death but, according to concentration and site of production, it 






















































Figure 7. (A) Carbonyl species levels (B) MDA+4-HDA levels (nmol mg-1 
protein) in Caco-2/TC7 cells with complexes 7 and 8 (24 h, 20 M). 
*P<0.05 vs. control. (n≥ 6 experiments)
Apoptosis studies in cancer cells. We thought that maybe this 
oxidative damage in the membrane lipids, as a consequence of the 
inhibition of the thioredoxin reductase enzyme, might promote 
apoptosis processes. Drugs can trigger different mechanisms of cell 
death, but apoptosis is the pathway responsible for the cell 
proliferation control; a hundred thousand cells are produced every 
second by mitosis processes, while an equivalent number of cells is 
destroyed by apoptotic processes.56 Consequently, several apoptosis 
assays were performed with the selective complexes 7 and 8. Firstly, 
we studied the ability of our compounds to induce apoptosis by flow 
cytometry, by using a combination of the markers 7-
Aminoactinomycin D (7-AAD) and annexin V-FITC. In apoptotic cells, 
the exposure of phosphatidylserine (PS) usually occurs prior to the 
loss of plasma membrane integrity,57, 58 so external PS can be defined 
as a marker of apoptosis.57, 59 Due to the selective reaction of PS with 
annexin, healthy cells will be unreactive. As it can be seen in Figure 
8B, both gold(I) complexes exhibit a slightly increase in population of 
cells undergoing apoptosis (in early and late stages) compared to 
control, although this increase was not statistically significant. Only a 
negligible percentage of necrotic cells was observed. 
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Figure 8. (A) Fluorescence histograms of the distribution of cell 
populations in different stages: necrosis (Q1), living cells (Q3), late 
apoptosis (Q2) and early apoptosis (Q4), in control and gold(I) 
complexes treated Caco-2/TC7 cells. (B) Apoptosis values, early + late, 
(%) of cells treated with gold(I) complexes (20 μM, 24 h). The results 
are expressed as mean ± SEM (n ≥ 4 experiments). 
Cell cycle Studies. The mutations responsible for the formation and 
growing of tumour are significantly controlled by the cell cycle. In 
fact, cancer cells usually imply changes in the normal performance 
of the cell cycle, and therefore studies of the cell cycle of Caco-2/TC7 
by using flow cytometry were carried out (Figure 9). The cell 
populations obtained in the histograms show that  most of cells are 
found in the G0/G1 phases, which is something normal, as cells 
spend the most part of their lives in these phases.60, 61 Comparing 
the values of the cells in the different stages of the cycle, no 
significant increase of the number of cells in S or G2/M phase was 
shown by complex 7 and 8. These results suggest that complexes 7 
and 8 might not alter the cell cycle in its action mechanisms (Table 
8). This fact was also observed with other different gold(I) complexes 
with no impact on the antiproliferative activity.62
Figure 9. Fluorescence histograms obtained by flow cytometry of 
the cell populations in different phases of the cell cycle after 24 h 
of incubation of the cells with DMSO (control) and  gold(I) 
complexes 7 and 8 (20 M).
Table 8. Cell populations (%) in the different phases of the cell 
cycle for complexes 7 and 8 (20 μM, 24 h).
G0/G1 S G2/M 
Control 60.25±1.53 33.02±1.25 6.73±0.55
7 59.51±4.42 34.67±4.39 5.05±0.49
8 60.89±4.23 30.63±3.50 8.48±1.22
Values are expressed as mean ± EEM (n ≥ 4 experiments). 
*P<0.05; **P<0.01 vs. control.
Apoptosis studies in primary cultures of mouse colon tumours. 
Once in vitro assays were performed, as the obtained apoptosis 
results were inconclusive, we decided to test our compounds in 
primary cultures of colon tumours from mice. This model allows us 
to test our complexes in conditions more similar to what happens 
in colon cancer. In this experimental model we employed dextran 
sodium sulfate (DSS) to induce epithelial damage in combination 
with azoxymethane (AOM), a potent carcinogenic that can 
produce colonic tumorigenesis in over a period of 10 weeks.63, 64 
The isolated tumor tissue was subjected to enzymatic digestion to 
obtain individual cancer cells. Then, the same protocol as in the in 
vitro model of cells was carried out to detect the exposure to 
phosphatidylserine. Surprisingly, working in a more real tumor 
model, the result was different in contrast to the in vitro 
experiment (Figure 10); now complex 7 and 8 can be considered 




















Figure 10. Apoptosis values, early + late, (%) of Caco-2 cells treated 
with gold(I) complexes (20 μM, 24 h). The results are expressed as 
mean ± SEM (n ≥ 4 experiments) *P<0.05; ***P<0.001 vs. control.
EXPERIMENTAL SECTION
General procedures 
NMR Spectroscopy. 1H, 31P and 13C NMR spectra were recorded on 
400 or 300 MHz Bruker Avance spectrometers and are referenced 
to external TMS or 85% H3PO4 (31P), Chemical shifts (δ) are given 
in ppm, coupling constants are reported in Hz. MALDI mass spectra 
were measured on a Micromass Autospec spectrometer in positive 
ion mode using DCTB (1,1-diciano-4-tbutylphenyl-3-
methylbutadiene) as matrix. Infrared spectra (4000-250 cm-1) 
were recorded on a Perkin Elmer Spectrum 100 FTIR (far-IR) 
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spectrometer. Elemental analyses were obtained in-house using a 
LECO CHNS-932 microanalyser. The starting material: the 
phosphane HMPT was purchased from Alfa Aesar (Kandel, 
Germany) and the thiols were purchased from Sigma-Aldrich 
(Madrid, Spain) and used as received. [AuCl(tht)] was prepared 
according to published methods,65 and [AuCl(HMPT)] with a 
slightly modified procedure.31 
WARNING: Special care must be taken with the phosphane, thus 
working in a well-ventilated place is extremely recommended.
Synthesis and Characterization.
[AuCl(HMPT)] (1). To a suspension of [AuCl(tht)] (2 mmol, 0.643 g) 
in 20 mL of acetone in a shlenk tube under argon was added 3 
mmol of HMPT (2 mmol, 0.489 g, 0.365 mL) and stirred for 1 h at 
room temperature. The resulting solution was evaporated until 
dryness and a white solid is observed. Yield: 93% white solid. 1H 
NMR (400 MHz, CDCl3) δ (ppm) 2.66 (d, JH-P = 11.7 Hz, 18H). 31P {1H} 
NMR (162 MHz, CDCl3) δ(ppm) 110.87 (s). APT-RMN (101 MHz, 
CDCl3) δ(ppm) 37.79 (d, JC-P=9.2 Hz) IR ((cm-1)): 2922, 1462, 1425, 
1408, 1281, 1179, 1149, 1063, 958, 719, 677, 523, 316. MS 
(MALDI+, m/z (%)):270.2 (58.8, [Au-PNMe2]+), 360.1 (46.2, [M-Cl]+), 
523.2 (100, [M-Cl+HMPT]+), 755.1 (22.1, [2M-Cl]+). S25ºC H2O 
(mg/L)= 496.6
Preparation of the complexes (2)-(8). To an ethanolic solution (20 
mL) of 2-mercaptopyridine (2), 2-mercaptopyrimidine (3), 4,6-
dimethyl-2-mercaptopyrimidine (4), 2-mercaptobenzothiazole (5), 
2-mercaptothiazoline (6), 2-mercaptobenzimidazole (7) and 2-
thiouracil (8) (0.3 mmol); was added a solution of KOH in ethanol 
(0.33 mmol). After 30 min of stirring, [AuClHMPT] (0.3 mmol, 0.119 
g) was added, and the mixture was stirred for 24 h at room 
temperature, and the KCl was filtered off. The colourless solution 
was then, evaporated until 5 mL and filtered the formed solid. 
[Au(2-Spy)HMPT] (2). Yield: 99% yellow solid. 1H-NMR (400 MHz, 
CDCl3): δ (ppm) 8.16 (ddd, J= 5.0, 1.9, 0.8 Hz, 1H, Hpy-H6), 7.44 (d, 
J=8.0 Hz, 1H, Hpy-H3), 7.26-7.20 (m, 1H, Hpy-H4), 6.77 (ddd, J=7.3, 
5.0, 1.1 Hz, 1H, Hpy-H5), 2.65 (dd, JH-P=11.6 Hz, 3.2 Hz, 18H, HMe) 
APT (100.62 MHz, CDCl3): δ (ppm) 128.83, 126.65, 118.07 (Cpy-C5), 
37.86 (d, JC-P =9.5Hz, CMe). 31P{1H}-NMR (162 MHz, CDCl3): δ (ppm) 
124.05 IR (ν (cm-1)): 2879, 1563, 1535, 1445, 1407, 1370, 1282, 
950, 716, 677, 631, 519. MS (MALDI+) m/z (%): 523.2 (47.0, 
[AuHMPT+HMPT]+), 830.1 (100, [M+AuHMPT]+), 1137.1 (3.6, 
[2M+Au]+). Anal. Calc. for C11H22AuN4PS: C, 28.09; H, 4.71; N, 
11.91; S, 6.82. Found: C, 28.22; H, 4.33; N, 11.77; S, 6.47%.
[Au(2-Spym)HMPT] (3). Yield: 98% pale yellow solid. 1H-NMR (400 
MHz, CDCl3): δ (ppm) 8.27 (d, J=4.8Hz, 2H, Hpy-H4), 6.76 (t, 
J=4.8Hz, 1H, Hpy-H5), 2.71 (d, JH-P=11.5 Hz, 18H, HMe) APT (100.62 
MHz, CDCl3): δ (ppm) 156.56 (Cpy-C4), 115.40 (Cpy-C5), 37.87 (d, 
JC-P =9.6Hz, CMe) 31P{1H}-NMR (162 MHz, CDCl3): δ (ppm) 124.05 IR 
(ν (cm-1)): 2918, 1561, 1535, 1369, 1283, 1186, 1169, 1063, 948, 
774, 740, 711, 678, 518. MS (MALDI+, m/z (%)): 523.2 (9.9, 
[AuHMPT+HMPT]+), 831.1 (100, [M+AuHMPT]+), 1139.2 (3.7, 
[2M+Au]+). Anal. Calc. for C10H21AuN5PS: C, 25.48; H, 4.49; N, 
14.86; S, 6.80. Found: C, 25.59; H, 4.44; N, 15.12; S, 7.01%.
[Au(4,6-dimethyl-2-Spym)HMPT] (4). Yield: 94% pale yellow solid 
1H-NMR (400 MHz, CDCl3): δ (ppm) 6.76 (s, 1H, Hpy-H3), 2.66 (d, J= 
11.7 Hz, 18H, HMe), 2.40 (d, JH-P=11.5 Hz, 6H, Hpy-HMe). APT 
(100.62 MHz, CDCl3): δ (ppm) 165.89 (Cpy-C3), 114.49 (Cpy-C4), 
37.90 (d, JC-P=9.7 Hz, CMe), 23.93 (Cpy-CMe). 31P{1H}-NMR (162 
MHz, CDCl3): δ (ppm) 124.43. IR (ν (cm-1)): 2895, 1619, 1573, 1540, 
1288, 1246, 971, 948, 719, 679, 520. MS (MALDI+) m/z (%): 523.2 
(4.6, [AuHMPT+HMPT]+), 859.1 (100, [M+AuHMPT]+), 1195.1 (7.4, 
[2M+Au]+). Anal. Calc. for C12H25AuN5PS: C, 28.86; H, 5.05; N, 
14.02; S, 6.42. Found: C, 28.99; H, 5.14; N, 14.25; S, 6.35%.
[Au(2-Sbenzothiazole)HMPT] (5). Yield: 97% white solid. 1H-NMR 
(400 MHz, CDCl3): δ (ppm) 7.69 (dd, J=8.1, 0.5 Hz, 1H, HPh-H7), 
7.60-7.52 (m, 1H, HPh-H4), 7.33-7.26 (m, 1H, HPh-H6), 7.15  (ddd, 
J= 7.9, 7.4, 1.2 Hz, 1H, HPh-H5), 2.71 (d, JH-P= 11.6 Hz, 18H, HMe). 
APT (100.62 MHz, DMSO): δ (ppm) 172.42, 155.96, 135.43, 125.56 
(CPh-C6), 123.37 (CPh-C3), 120.51 (CPh-C4), 119.73 (CPh-C7), 
37.17 (d, JC-P =8.7Hz, CMe). 31P{1H}-NMR (162 MHz, CDCl3): δ (ppm) 
121.66. IR (ν (cm-1)): 3053, 2920, 2881, 1630, 1557, 1447,1413, 
1281, 1182, 1059, 966, 720, 677, 520. MS (MALDI+) m/z (%):523.2 
(100, [AuHMPT+HMPT]+), 886.1 (44.5, [M+AuHMPT]+). Anal. Calc. 
for C13H22AuN4PS2: C, 29.66; H, 4.21; N, 10.64; S, 12.18. Found: C, 
29.82; H, 4.25; N, 10.46; S, 12.39%.
[Au(2-Sthiazoline)HMPT] (6). Yield: 97% white solid. 1H-NMR (400 
MHz, CDCl3): δ (ppm) 4.24 (t, J=7.9 Hz, 2H, Hthiazol-H5), 3.37  (t, 
J=7.9 Hz, 2H, Hthiazol-H4), 2.70 (d, JH-P= 11.6 Hz, 18H, HMe). APT 
(100.62 MHz, DSMO): 65.62 (Cthiazol-C5), 37.83 (d, JC-P =9.2 Hz, 
CMe), 36.47 (Cthiazol-C4). 31P{1H}-NMR (162 MHz, CDCl3): 122.80.  
IR (ν (cm-1)): 3070, 2922, 2882, 1636, 1547, 1450, 1280, 1181, 
1151, 962, 712, 670, 517. MS (MALDI+) m/z (%): 523.0 (37.5, 
[AuHMPT+HMPT]+), 837.8 (79.0, [M+AuHMPT]+), 1111.8 (100, 
[M+AuHMPT+AuPN]+). Anal. Calc. for C9H20AuN4PS2: C, 22.69; H, 
4.23; N, 11.76; S, 13.36. Found: C, 22.85; H, 4.19; N, 11.89; S, 
13.66%.
[Au(2-Sbenzimidazole)HMPT] (7). Yield: 89% white solid. 1H-NMR 
(400 MHz, CDCl3): δ (ppm) 7.37-7.31 (m, 2H, HPh-H4), 7.11-7.05 
(m, 2H, HPh-H5), 2.71 (d, JH-P= 11.6 Hz, 18H, HMe). APT (100.62 
MHz, CDCl3): δ (ppm) 121.28 (CPh-C4), 112.76 (CPh-C5), 37.85 (d, 
JC-P=9.3 Hz, CMe). 31P{1H}-NMR (162 MHz, CDCl3): δ (ppm) 120.78. 
IR (ν (cm-1)): 2881, 2835, 2791, 1425, 1270, 1184, 968, 717, 679, 
520. MS (MALDI+) m/z (%): 523.2 (27.4, [AuHMPT+HMPT]+), 869.1 
(39.1, [M+AuHMPT]+), 1228.3 (100, [M+ 2AuHMPT]+). Anal. Calc. 
for C13H23AuN5PS: C, 30.65; H, 4.55; N, 13.75; S, 6.30. Found: C, 
30.77; H, 4.61; N, 38.91; S, 6.61%.
[Au(2-thiouracile)HMPT] (8). Yield: 94% white solid. 1H-NMR (400 
MHz, CDCl3): δ (ppm) 7.62 (d, J=6.7 Hz, 1H, Hthio-H5), 6.06 (d, J=6.7 
Hz, 1H, Hthio-H4), 2.70 (d, JH-P= 11.6 Hz, 18H, HMe). APT (100.62 
MHz, DSMO): δ (ppm) 109.84, 37.79 (d, JC-P= 9.2 Hz, CMe). 31P{1H}-
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NMR (162 MHz, CDCl3): δ (ppm) 120.88. IR (ν (cm-1)): 3323, 3084, 
2971, 2882, 1655, 1566, 1448, 1046, 968, 719, 677, 522. MS 
(MALDI+) m/z (%): 523.2 (100, [AuHMPT+HMPT]+), 847.2 (8.7, 
[M+AuHMPT]+). Anal. Calc. for C10H21AuN5OPS: C, 24.65; H, 4.34; 
N, 14.37; S, 6.58. Found: C, 24.79; H, 4.37; N, 14.58; S, 6.72%.
Single-Crystal Structure Determination. Suitable crystals of 4, 5 
and 8 were mounted on a glass fiber and used for data collection 
on a Bruker AXS APEX CCD area detector equipped with graphite 
monochromated Mo K radiation ( = 0.71073 Å) by applying the 
-scan method. Lorentz-polarization and empirical absorption 
corrections were applied. The data reduction was performed with 
the APEX2 software (Bruker Apex2, Bruker AXS Inc., Madison, 
Wisconsin, USA, 2004) and corrected for absorption using SADABS 
(G.M. Sheldrick, SADABS, Program for Empirical Adsorption 
Correction, Institute for Inorganic Chemistry, University of 
Gottingen, Germany, 1996). Crystal structure was solved by direct 
methods and refined by full-matrix least-squares on F2 including all 
reflections using anisotropic displacement parameters by means 
of the WINGX crystallographic package (G. M. Sheldrick, SHELX-
2014, Program for Crystal Structure Refinement, University of 
Göttingen, Göttingen, Germany, 2014).66 Generally, anisotropic 
temperature factors were assigned to all atoms except for 
hydrogen atoms, which are riding their parent atoms with an 
isotropic temperature factor arbitrarily chosen as 1.2 times that of 
the respective parent. Final R(F), wR(F2) and goodness of fit 
agreement factors, details on the data collection and analysis can 
be found in Table S1. Selected bond lengths and angles are given 
in Table S2 (ESI). CCDC reference numbers for the structures of 4 
and 5 were 1938214 and 1938215.  The quality of the crystals in 
compound 8 was very low. Several samples have been measured 
and their structural properties have been studied. This cif file is 
included in the supporting information and has not been deposited 
in the CCDC. Copies of the data can be obtained free of charge 
upon application to CCDC, 12 Union Road, Cambridge CB2 1EZ, 
U.K. (fax, (+44)1223 336-033; e-mail, deposit@ ccdc.cam.ac.uk).
Cell culture. This study was carried out in the human enterocyte-
like cell line Caco-2/TC7.67 This cell line undergoes in culture a 
process of spontaneous differentiation that leads to the formation 
of a monolayer of cells, expressing morphological and functional 
characteristics of the mature enterocytes. This differentiation 
process is growth-dependent, where the cells undergo 
differentiation from 'undifferentiated proliferative crypt-type 
cells' in exponential phase of growth, to 'differentiated 
enterocyte-type cells' in stationary phase.68 Caco-2/TC7 cells 
(passages 30-50) were cultured at 37ºC in an atmosphere of 5% 
CO2 and maintained in high glucose DMEM supplemented with 2 
mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1% 
non-essential amino acids, and 20% heat-inactivated fetal bovine 
serum (FBS) (Life Technologies, Carlsbad, CA, USA). To cell line 
maintenance, cells were passaged enzymatically with 0.25% 
trypsin-1 mM EDTA and sub-cultured on 25 cm2 plastic flasks at a 
density of 104 cells/cm2. Culture medium was replaced every 2 
days. With this density of culture, the cells reach cell confluence 
90% (where cell differentiation starts) at 7 days after seeding, and 
the complete cell differentiation is reached at 15 days post-
seeding. Thus, experiments in undifferentiated and differentiated 
cells (considered as cancer and normal cells, respectively) were 
performed between 2-5 days and 12-15 days post-seeding, 
respectively. For cell viability assays, cells were seeded in 96-well 
plates at a density of 2 × 104 or 4 × 103 cells per well, and 
measurements were carried out 5 or 15 days after seeding, 
respectively. For thioredoxin reductase and oxidative stress 
assays, cells were seeded at a density of 3.3 × 104 cells/cm2; and 
for apoptosis and cell cycle analyses at 3 × 104 cells/cm2. Stock 
solutions of the complexes (in DMSO) were diluted in the complete 
medium to the required concentration. DMSO at similar 
concentrations did not show any cytotoxic effects. The culture 
medium was replaced with fresh medium (without FBS) containing 
the complexes at concentrations varying from 0 to 20 μM, and with 
an exposure time of 72 h for cell viability assays. For all the other 
studies, the cells were incubated at 20 μM for 24 h.
Cell viability assay. Cell survival was measured by using the MTT 
test.43 The assay is dependent on the cellular reduction of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 
Sigma-Aldrich, Madrid, Spain) by the mitochondrial 
dehydrogenase of viable cells to a blue formazan product that can 
be measured spectrophotometrically. Following the appropriate 
incubation of cells, with or without the metallic complexes, MTT (5 
mg mL-1) was added to each well in an amount equal to 10 % of the 
culture volume. Cells were incubated with MTT at 37 °C for 3 h. 
After that, the medium and MTT were removed and 100 μl of 
DMSO was added to each well. The plate was gentle stirred in a 
shaker. Finally, the cell viability was determined by measuring the 
absorbance with a multi-well spectrophotometer (DTX 800 
Multimode Detector, Beckman Coulter) at a wavelength of 560 nm 
and compared with the values of control cells incubated in the 
absence of the complexes. IC50 values were calculated using a 
conventional concentration-response curve with variable slope. 
Experiments were conducted in quadruplicate wells and repeated 
at least three times.
Apoptosis studies. For the studies of apoptosis, by means of the 
detection of phosphatidylserine in the outer layer of the plasma 
membrane, the Annexin V-FITC Apoptosis Detection kit 
(Immunostep, Spain) was used. After the incubation with the 
complexes, the cells were collected and transferred to flow-
cytometry tubes. A negative control was prepared with untreated 
cells, that was used to define the basal level of apoptotic and 
necrotic or dead cells. The staining with Annexin V-FITC and 7-
Aminoactinomycin D (7-ADD) was performed according to 
manufacturer’s recommendation. The cells were washed twice 
with temperate phosphate-buffered saline (PBS) and resuspended 
in 200 μl of 1 x Annexin-binding buffer. Thereafter, 2.5 μl of the 
Annexin V-FITC and 2.5 μl of PI were added to each 50 μl of cell 
suspension. After incubation for 15 min at RT in the dark, 400 μl of 
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1 x Annexin binding buffer were added and analyzed by flow 
cytometry within 1 h. The signal intensity was measured using a 
Gallios Flow Cytometry (Beckman Coulter) and analyzed using the 
Kaluza Analysis Software (Beckman Coulter).
Cell cycle analyses. After the incubation with the complexes, the 
cells were collected, washed twice with PBS, fixed in 70% ice-cold 
ethanol and stored at 4 °C for 24 h. After centrifugation, cells were 
resuspended in PBS containing propidium iodide (PI, 50 μg/mL) 
and RNase A (100 μg/mL). After incubation for 30 min at RT in the 
dark, PI stained cells were analyzed for DNA content in a Gallios 
Flow Cytometry (Beckman Coulter). The red fluorescence emitted 
by PI was collected by 620 nm longer pass filter, as a measure of 
the amount of DNA-bound PI and displayed on a linear scale. Cell 
cycle distribution was determined on a linear scale. The 
percentage of cells in cycle phases was determined using the 
Kaluza Analysis Software (Beckman Coulter).
Cell homogenates preparation. After the incubation with the 
complexes, the cells were resuspended and homogenized with a 
cold Tris-mannitol buffer (Tris 2 mM, mannitol 50 mM, pH 7.1, 
protease inhibitors, and 0.02% sodium azide). Then, the 
homogenate was disrupted by sonication (15 1-s bursts, 60 W). For 
lipid peroxidation and protein carbonyl analysis, the homogenate 
was centrifuged for 10 min at 3,000 g at 4°C and for thioredoxin 
reductase activity determination, the homogenate was 
centrifuged for 10 min at 10,000 g at 4°C. The supernatant was 
taken for the study. Protein content was measured by following 
the Bradford method (Bio-Rad, Hercules, CA, USA). 
Measurement of lipid and protein oxidation. The level of lipid 
peroxidation was determined by measuring the concentration of 
malondialdehyde (MDA) and 4- hydroxyalkenals (4-HDA), as 
described previously.69 Briefly, MDA+4-HDA reacted with N-
methyl-2-phenylindole and yielded a stable chromophore that was 
measured in a spectrophotometer at 586 nm, using 1,1,3,3-
tetramethoxypropane as standard. The results were calculated in 
nmol MDA+4-HDA mg-1 protein. Protein oxidation was analyzed by 
carbonyl level measurement as previously described.70 Cell 
homogenates were incubated with the classical carbonyl reagent 
2,4-dinitrophenylhydrazine (DNPH), and protein carbonylation 
was measured spectrophotometrically at 375 nm. The results were 
calculated in nmol carbonyl groups mg-1 protein.
Thioredoxin reductase activity. Thioredoxin reductase (TrxR) 
activity was determined by the Thioredoxin Reductase Assay Kit 
(Sigma-Aldrich, Madrid, Spain) according to the manufacturer’s 
instructions. It is based on the reduction of 5,5´-dithiobis(2-
nitrobenzoic) acid (DTNB) with NADPH to 5-thio-2-nitrobenzoic 
acid (TNB), which produces a strong yellow colour that is measured 
at 412 nm. The reaction mixture contained 50 l of the sample, 
100 mM potassium phosphate buffer at pH 7.0 with 10 mM EDTA 
and 0.24 mM NADPH, with and without a TrxR inhibitor, to 
complete a final volume of 970 µl. The reaction was started by 
adding 30 µl DTNB (39.6 mg mL-1) and the absorbance change at 
412 nm was monitored for 5 min with the spectrophotometer 
Hitachi U-2800A Spectrophotometer UV-vis Reader. The number 
of units was calculated by using Beer's Law and an extinction 
coefficient of 14.150 M−1cm−1 for the TNB anion. One unit of TrxR 
activity is the amount of enzyme catalyzing the reduction of 1 
equivalent of DTNB per min at 25 ºC, pH 7 (formation of 2 
equivalents of TNB anion). The specific activity of TrxR was 
calculated as units per mg of total protein.
Mouse model of colitis-associated cancer. All procedures were 
carried out under Project License PI43/17, approved by the in-
house Ethics Committee for Animal Experiments from the 
University of Zaragoza. The care and use of animals were 
performed accordingly with the Spanish Policy for Animal 
Protection RD53/2013, which meets the European Union Directive 
2010/63 on the protection of animals used for experimental and 
other scientific purposes. Female Hsd:ICR (CD-1) mice (16-week-
old) were purchased from Envigo (Barcelona, Spain). All mice were 
housed in Servicio de Experimentación Animal of the Universidad 
de Zaragoza, Spain, on a 12-hour light/dark cycle with food and 
water ad libitum. Mice were intraperitoneally injected with a 
single dose of 12 mg/kg azoxymethane (AOM) (Sigma-Aldrich, 
Madrid, Spain) on day 1, followed by three cycles of dextran sulfate 
sodium (DSS) MW 40 kDa (Sigma-Aldrich, Madrid, Spain) 
administration (Each cycle: 3% DSS during 5 days, followed of 
drinking water during 16 days), and then drinking water until the 
end of the experiment on week 10-14. 
Primary cultures of mouse colonic tumors. Colonic tumors were 
isolated from the mice treated with the above AOM/DSS protocol 
(2-3 tumors/mouse) and collected in DMEM medium 
supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 25 L/mL antibiotic/antimycotic (100x) and 50 
µg/mL gentamycin. Tumors were cut into pieces and processed for 
enzymatic digestion in culture medium with 5 % FBS supplemented 
with 2 mM glutamine, insulin 4 µg/mL, dispase I 0.08 mg/mL, 
collagenase 0.04 mg/mL and EGF 0.01 µg/mL for 3-4 hours at 37°C 
in rotation. Tissue masses were washed twice, resuspended in 
complete medium with 25% FBS supplemented with 2 mM 
glutamine, insulin 4 µg/mL and EGF 0.01 µg/mL, seeded onto 96-
well plates at a density of 105 cells per well, and incubated for 72 
h at 37°C and in 5% CO2. The medium was changed 72 h after 
seeding and every two days thereafter. The experiments of 
apoptosis (detection of phosphatidylserine with Annexin V-FITC) 
were carried out in the cells 7 days after seeding, following the 
above protocol.
Statistical Analyses. All results are expressed as means ± the 
standard error of the mean (SEM) of at least three independent 
experiments. Statistical comparisons were performed using 
Student's t-test or one-way ANOVA followed by the Bonferroni 
posttest and the differences between P-values<0.05 were 
considered statistically significant. Statistical analyses were carried 
out using the Prism GraphPad Program (Prism version 4.0, 
GraphPad Software, San Diego, CA).
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CONCLUSIONS
In this work, we describe the synthesis of seven novel thiolate 
gold(I) complexes with the water soluble phosphane HMPT. After 
their structural characterization by the typical techniques 
including X-ray diffraction for complexes 4, 5 and 8, we have 
evaluated some of their physicochemical properties of the ADME-
tox profile such as thermal stability, water solubility, lipophilicity, 
interaction with BSA, and their antiproliferative activity. All of our 
complexes showed much more cytotoxic activity than cisplatin in 
A2780 and A2780R cell lines, and analogous studies with Caco-
2/TC7 cells pointed the same tendency. This study with Caco-2 
showed that the use of HMPT phosphane instead of PTA 
derivatives implies more antiproliferative effect up to 10 times in 
some cases. Besides, two of the gold(I) complexes (complex 7 and 
8) are no toxic drugs for considered normal epithelial cells 
(differentiated Caco-2/TC7 cells). In addition of these studies, their 
mechanism of action was carefully investigated. Oxidative stress 
studies revealed that these two complexes induce a strong 
inhibition of the antioxidant system TrxR and an oxidative damage 
in membrane lipids. These complexes do not seem to induce 
apoptosis in undifferentiated cancer Caco-2/TC7 cells through the 
phosphatidylserine signaling pathway or by the alteration of cell 
cycle. However, we do detect a phosphatidylserine externalization 
in the cells from primary cultures of mouse colon tumors, in 
contrast to the in vitro studies, indicating that complexes 7 and 8 
induce apoptosis. All of our studies point that complexes 7 and 8 
might be promising candidates to use as treatment in colon cancer 
chemotherapy.
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